Lexeo Therapeutics (LXEO) Cash & Current Investments (2022 - 2026)
Lexeo Therapeutics recorded quarterly Cash & Current Investments of $193.0 million in Q1 2026, up 6.2% quarter-over-quarter from $181.8 million in Q4 2025, and up 93.37% year-over-year from $99.8 million in Q1 2025.
Lexeo Therapeutics' Cash & Current Investments history runs 5 years deep, the most recent figure standing at $193.0 million for Q1 2026.
- In Q1 2026, Cash & Current Investments rose 93.37% year-over-year to $193.0 million; the TTM figure through Mar 2026 stood at $193.0 million (up 93.37% YoY), while the FY2025 annual figure was $181.8 million, up 49.58% from the prior year.
- Cash & Current Investments came in at $193.0 million for Q1 2026 at Lexeo Therapeutics, up from $181.8 million in the prior quarter.
- In the past five years, Cash & Current Investments ranged from a high of $195.1 million in Q1 2024 to a low of $35.4 million in Q3 2023.
- A 5-year average of $131.3 million and a median of $122.8 million in 2025 frame the typical range for Cash & Current Investments.
- Across the five-year window, Cash & Current Investments sank 62.35% in 2023 and soared 342.89% in 2024, its largest moves.
- Lexeo Therapeutics' Cash & Current Investments stood at $77.3 million in 2022, then jumped by 57.06% to $121.5 million in 2023, then climbed by 0.04% to $121.5 million in 2024, then surged by 49.58% to $181.8 million in 2025, then climbed by 6.2% to $193.0 million in 2026.
- According to Business Quant data, Cash & Current Investments over the past three periods registered $193.0 million, $181.8 million, and $122.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 2.13 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 7.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 8.75 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 3.01 Bn |
| 10 | Lexeo Therapeutics | 392.12 Mn | 199.07 Mn | - | 193.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 193.04 Mn |
| Dec 31, 2025 | 181.77 Mn |
| Sep 30, 2025 | 122.76 Mn |
| Jun 30, 2025 | 132.89 Mn |
| Mar 31, 2025 | 99.83 Mn |
| Dec 31, 2024 | 121.52 Mn |
| Sep 30, 2024 | 157.00 Mn |
| Jun 30, 2024 | 175.00 Mn |
| Mar 31, 2024 | 195.10 Mn |
| Dec 31, 2023 | 121.47 Mn |
| Sep 30, 2023 | 35.45 Mn |
| Dec 31, 2022 | 77.34 Mn |
| Sep 30, 2022 | 94.15 Mn |